COPD anno 2011: Emphasis on bronch(iol)odilation

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 3, 2012, Pages 148-153

  Lahaije, Anke J M C ^a   Heijdra, Yvonne F ^a   Willems, Laura M ^a   Van Helvoort, Hanneke A C ^a   Dekhuijzen, Richard ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

bronchodilation; exercise capacity; physical activity

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CARBON MONOXIDE; FENOTEROL; FLUTICASONE; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ADD ON THERAPY; ANXIETY; BEHAVIOR; BLOOD PRESSURE; BREATHING MUSCLE; BRONCHODILATATION; BRONCHUS OBSTRUCTION; CACHEXIA; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DAILY LIFE ACTIVITY; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DRUG MECHANISM; DYSPNEA; ENVIRONMENTAL FACTOR; EXERCISE; FIBROSIS; FORCED EXPIRATORY VOLUME; GLAUCOMA; HEALTH STATUS; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERINFLATION; INSPIRATORY RESERVE VOLUME; LUNG DIFFUSION CAPACITY; LUNG EDEMA; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG PARENCHYMA; LUNG VOLUME; LYMPHOCYTE; MACROPHAGE; METABOLIC SYNDROME X; METERED DOSE INHALER; MORBIDITY; MORTALITY; MUSCLE ATROPHY; NEUTROPHIL; OSTEOPOROSIS; PARTICLE SIZE; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; POWDER INHALER; RESPIRATORY AIRFLOW; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIDE EFFECT; TIDAL VOLUME; URINE RETENTION; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; BRONCHODILATOR AGENTS; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; HUMANS; MOTOR ACTIVITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84862276322     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0922     Document Type: Review

References (68)

1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, and Mannino DM: Global burden of COPD: Systematic review and meta-Analysis. Eur Respir J. 2006;28:523-532. (Pubitemid 44794666)
2. World Health Statistics 2008: Geneva, Switzerland: WHO Press; 2008. Available at: Http://www.who.int/respiratory/copd/World-Health-Statistics-2008/ en/index.html
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, and Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-555. (Pubitemid 47403272)
4. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, and Rochat T: Long-Term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63:768-774.
5. De Marco R, Accordini S, Anto JM, Gislason T, Heinrich J, Janson C, Jarvis D, Kunzli N, Leynaert B, Marcon A, Sunyer J, Svanes C, Wjst M, and Burney P: Long-Term outcomes in mild/moderate chronic obstructive pulmonary disease in the European Community Respiratory Health Survey. Am J Respir Crit Care Med. 2009;180:956-963.
6. Decramer M, and Cooper CB: Treatment of COPD: The sooner the better? Thorax. 2010;65:837-841.
7. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler-Cataluñ a JJ, Van Der Molen T, Adamek L, and Banik N: Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105:57-66.
8. Ofir D, Laveneziana P, Webb KA, Lam YM, and O Donnell DE: Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177: 622-629. (Pubitemid 351442169)
9. Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, Benzo R, Andre D, Weisman I, and Decramer M: Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010;104:1005-1011.
10. Watz H, Waschki B, Meyer T, and Magnussen H: Physical activity in patients with COPD. Eur Respir J. 2009;33:262-272.
11. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, and Gosselink R: Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972-977. (Pubitemid 40616945)
12. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, and Anto JM: Risk factors of readmission to hospital for a COPD exacerbation: A prospective study. Thorax. 2003;58:100-105. (Pubitemid 36182995)
13. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, and Anto JM: Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: A population based cohort study. Thorax. 2006;61:772-778. (Pubitemid 44369401)
14. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, and Gosselink R: Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129:536-544.
15. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, and Magnussen H: Physical activity is the strongest predictor of all-cause mortality in patients with chronic obstructive pulmonary disease: A prospective cohort study. Chest. 2011;140:331-342.
16. Garcia-Aymerich J, Serra I, Gomez FP, Farrero E, Balcells E, Rodriguez DA, De Batlle J, Gimeno E, Donaire-Gonzalez D, Orozco-Levi M, Sauleda J, Gea J, Rodriguez-Roisin R, Roca J, Agusti AG, and Anto JM: Physical activity and clinical and functional status in COPD. Chest. 2009;136:62-70.
17. Magnussen H, and Watz H: Systemic inflammation in chronic obstructive pulmonary disease and asthma: Relation with comorbidities. Proc Am Thorac Soc. 2009;6:648-651.
18. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, and Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250-255. (Pubitemid 46203128)
19. Man SFP, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, and Sin DD: C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849-853. (Pubitemid 44570304)
20. Barnes PJ, and Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165-1185.
21. Mannino DM, Thorn D, Swensen A, and Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32: 962-969.
22. Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, Wouters E, Sethi S, and Cooper CB: COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5:235-256.
23. Dyspnea: Mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med. 1999;159: 321-340.
24. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, and Izumi T: A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest. 1999;116:1632-1637. (Pubitemid 30012705)
25. Cooper CB: The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006;119:21-31. (Pubitemid 44425292)
26. O Donnell DE, and Webb KA: The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol. 2008;105:753-755.
27. Barbera JA, Ramirez J, Roca J, Wagner PD, Sanchez-Lloret J, and Rodriguez-Roisin R: Lung structure and gas exchange in mild chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990;141:895-901. (Pubitemid 20157716)
28. Polkey MI, Kyroussis D, Hamnegard CH, Mills GH, Green M, and Moxham J: Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 154:1310-1317. (Pubitemid 26391174)
29. O Donnell DE, and Webb KA: Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis. 1993;148:1351-1357. (Pubitemid 23326038)
30. Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709-721. (Pubitemid 39140629)
31. O Donnell DE, Hamilton AL, and Webb KA: Sensorymechanical relationships during high-intensity, constantwork-rate exercise in COPD. J Appl Physiol. 2006;101: 1025-1035. (Pubitemid 44497544)
32. Krieger BP: Hyperinflation and intrinsic positive end-expiratory pressure: Less room to breathe. Respiration. 2009;77:344-350.
33. Jolley CJ, and Moxham J: A physiological model of patientreported breathlessness during daily activities in COPD. Eur Respir Rev. 2009;18:66-79.
34. O Donnell DE, Voduc N, Fitzpatrick M, and Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:86-94. (Pubitemid 39029073)
35. Hannink JD, Van Helvoort HA, Dekhuijzen PN, and Heijdra YF: Dynamic hyperinflation during daily activities: Does COPD global initiative for chronic obstructive lung disease stage matter? Chest. 2010;137:1116-1121.
36. Lahaije A, Van Helvoort H, Dekhuijzen P, and Heijdra Y: Physiologic limitations during daily life activities in COPD patients. Respir Med. 2010;104:1152-1159.
37. Vaes AW, Wouters EF, Franssen FM, Uszko-Lencer NH, Stakenborg KH, Westra M, Meijer K, Schols AM, Janssen PP, and Spruit MA: Task-related oxygen uptake during domestic activities of daily life in patients with COPD and healthy elderly subjects. Chest. 2011;140:970-979.
38. Dykstra BJ, Scanlon PD, Kester MM, Beck KC, and Enright PL: Lung volumes in 4,774 patients with obstructive lung disease. Chest. 1999;115:68-74. (Pubitemid 29047055)
39. O Donnell DE, Revill SM, and Webb KA: Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164: 770-777. (Pubitemid 32881912)
40. Guenette JA, Jensen D, Webb KA, Ofir D, Raghavan N, and O Donnell DE: Sex differences in exertional dyspnea in patients with mild COPD: Physiological mechanisms. Respir Physiol Neurobiol. 2011;177:218-227.
41. Spurzem JR, and Rennard SI: Pathogenesis of COPD. Semin Respir Crit Care Med. 2005;26:142-153. (Pubitemid 40617293)
42. Hogg JC, and Timens W: The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435-459.
43. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, and Paré PD: The nature of small-Airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653. (Pubitemid 38787999)
44. Deesomchok A, Webb KA, Forkert L, Lam YM, Ofir D, Jensen D, and O Donnell DE: Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD. 2010;7:428-437.
45. Gosselink JV, Hayashi S, Elliott WM, Xing L, Chan B, Yang L, Wright C, Sin D, Paré PD, Pierce JA, Pierce RA, Patterson A, Cooper J, and Hogg JC: Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:1329-1335.
46. Hogg JC, McDonough JE, Sanchez PG, Cooper JD, Coxson HO, Elliott WM, Naiman D, Pochettino M, Horng D, Gefter WB, and Wright AC: Micro-computed tomography measurements of peripheral lung pathology in chronic obstructive pulmonary disease. Proc AmThorac Soc. 2009;6:546-549.
47. Celli BR, and MacNee W: Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946. (Pubitemid 38807371)
48. Barnes PJ: The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117(Suppl 12A):24S-32S.
49. Johnson M: Beta2-Adrenoceptors: Mechanisms of action of beta2-Agonists. Paediatr Respir Rev. 2001;2:57-62.
50. Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, and Pascoe S: Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009;22:492-496.
51. Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, and Siafakas N: Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Curr Med Res Opin. 2004;20:581-586. (Pubitemid 38685000)
52. Celli B, ZuWallack R, Wang S, and Kesten S: Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-1748. (Pubitemid 37433567)
53. Van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, and Cornelissen PJ: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129:509-517.
54. Clark AR, and Hollingworth AM: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med. 1993;6:99-110. (Pubitemid 23231366)
55. Tarsin WY, Pearson SB, Assi KH, and Chrystyn H: Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006;316:131-137.
56. Weuthen T, Roeder S, Brand P, Mullinger B, and Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med. 2002;15:297-303.
57. Taki M, Marriott C, Zeng XM, and Martin GP: Aerodynamic deposition of combination dry powder inhaler formulations in vitro: A comparison of three impactors. Int J Pharm. 2010;388:40-51.
58. Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G, and Scheuch G: Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007;47: 1335-1341. (Pubitemid 47459668)
59. Zierenberg B, and Eicher J: Modified-release drug delivery technology. In: M Rathbone, J Hadgraft, and M Roberts M (eds). Drugs and the Pharmaceutical Sciences. 2nd ed. New York: Informa Health; 2003.
60. Miravitlles M, and Anzueto A: Insights into interventions in managing COPD patients: Lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulm Dis. 2009;4:185-201.
61. Aliverti A, and Macklem PT: The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles. J Appl Physiol. 2008;105: 749-751.
62. Debigare R, and Maltais F: The major limitation to exercise performance in COPD is lower limb muscle dysfunction. J Appl Physiol. 2008;105:751-753.
63. Casaburi R, and Porszasz J: Reduction of hyperinflation by pharmacologic and other interventions. Proc AmThorac Soc. 2006;3:185-189.
64. Belman MJ, Botnick WC, and Shin JW: Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:967-975. (Pubitemid 26081647)
65. O Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, and Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-840. (Pubitemid 38807355)
66. O Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, and Kramer B: Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105:1030-1036.
67. O Donnell DE, Laveneziana P, Ora J, Webb KA, Lam YM, and Ofir D: Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax. 2009;64:216-223.
68. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, and Kesten S: Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809-817. (Pubitemid 40775509)